Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 19/20 | 0.59 |
| ▸ | CDK2 | P24941 | 19/20 | 0.59 |
| ▸ | CCND1 | P24385 | 13/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 13/20 | 0.59 |
| ▸ | CDK4 | P11802 | 8/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.59 |
| ▸ | CDK9 | P50750 | 8/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.54 |
| ▸ | CCND3 | P30281 | 2/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26340922 | 0.85 | CCND1 (0.60) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26341054 | 0.85 | CCND1 (0.60) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26340824 | 0.85 | CCND1 (0.60) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26941919 | 0.81 | CCNE1 (0.62) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL29593949 | 0.81 | CCNE1 (0.54) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26340940 | 0.80 | CCNE1 (0.60) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26340844 | 0.80 | CCNE1 (0.60) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26340941 | 0.80 | CCNE1 (0.60) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26341270 | 0.79 | CCNE1 (0.58) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30804793 | 0.79 | CDK2 (0.58) | CCNE1CDK2CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | DPYD, TYMS, TYMP | CCNE1 1815/4885CDK2 165/4885CCND1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.